Skip to main content

Table 6 Adverse events by body system, n (%)

From: Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination

 

All causality adverse events

N = 391

Treatment-related adverse events

N = 391

Any adverse event

89 (22.8)

60 (15.3)

Discontinued due to adverse event

22 (5.6)

20 (5.1)

System Organ Class

  

   Cardiac disorders

3 (0.8)

2 (0.5)

   Ear and labyrinth disorders

4 (1.0)

3 (0.8)

   Eye disorders

40 (10.2)

34 (8.7)

   Gastrointestinal disorders

6 (1.5)

3 (0.8)

   General disorders and administration site conditions

11 (2.8)

8 (2.0)

   Immune system disorders

2 (0.5)

2 (0.5)

   Infections and infestations

8 (2.0)

1 (0.3)

   Injury, poisoning, and procedural complications

2 (0.5)

1 (0.3)

   Investigations

2 (0.5)

2 (0.5)

   Metabolism and nutrition disorders

1 (0.3)

1 (0.3)

   Musculoskeletal and connective tissue disorders

2 (0.5)

-

   Nervous system disorders

12 (3.1)

8 (2.0)

   Psychiatric disorders

8 (2.0)

6 (1.5)

   Reproductive system and breast disorders

1 (0.3)

1 (0.3)

   Respiratory, thoracic, and mediastinal disorders

4 (1.0)

3 (0.8)

   Skin and subcutaneous tissue disorders

10 (2.6)

9 (2.3)

   Surgical and medical procedures

2 (0.5)

-

   Vascular disorders

6 (1.5)

2 (0.5)